Detection and tracking of NY-ESO-1-Specific CD8+ T cells by high-throughput T cell receptor β (TCRB) gene rearrangements sequencing in a peptide-vaccinated patient

Manami Miyai, Shingo Eikawa, Akihiro Hosoi, Tamaki Iino, Hirokazu Matsushita, Midori Isobe, Akiko Uenaka, Heiichiro Udono, Jun Nakajima, Eiichi Nakayama, Kazuhiro Kakimi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Comprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high responder patient (TK-f01) in an NY-ESO-1f peptide vaccine study, we performed high-throughput T cell receptor β-chain (TCRB) gene next generation sequencing (NGS) to monitor the frequency of NY-ESO-1-specific CD8+ T cells. We compared these results with those of conventional immunological assays, such as IFN-γ capture, tetramer binding and limiting dilution clonality assays. We sequenced human TCRB complementarity-determining region 3 (CDR3) rearrangements of two NY-ESO-1fspecific CD8+ T cell clones, 6-8L and 2F6, as well as PBMCs over the course of peptide vaccination. Clone 6-8L possessed the TCRB CDR3 gene TCRBV11-03∗01 and BJ02- 01∗01 with amino acid sequence CASSLRGNEQFF, whereas 2F6 possessed TCRBV05- 08∗01 and BJ02-04∗01 (CASSLVGTNIQYF). Using these two sequences as models, we evaluated the frequency of NY-ESO-1-specific CD8+ T cells in PBMCs ex vivo. The 6-8L CDR3 sequence was the second most frequent in PBMC and was present at high frequency (0.7133%) even prior to vaccination, and sustained over the course of vaccination. Despite a marked expansion of NY-ESO-1-specific CD8+ T cells detected from the first through 6th vaccination by tetramer staining and IFN-γ capture assays, as evaluated by CDR3 sequencing the frequency did not increase with increasing rounds of peptide vaccination. By clonal analysis using 12 day in vitro stimulation, the frequency of B∗52:01-restricted NYESO- 1f peptide-specific CD8+ T cells in PBMCs was estimated as only 0.0023%, far below the 0.7133% by NGS sequencing. Thus, assays requiring in vitro stimulation might be underestimating the frequency of clones with lower proliferation potential. High-throughput TCRB sequencing using NGS can potentially better estimate the actual frequency of antigen- specific T cells and thus provide more accurate patient monitoring.

Original languageEnglish
Article numbere0136086
JournalPLoS One
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 20 2015

Fingerprint

T-Cell Receptor Genes
T-cells
Gene Rearrangement
T-Cell Antigen Receptor
Complementarity Determining Regions
T-lymphocytes
Genes
Throughput
peptides
T-Lymphocytes
Peptides
receptors
Vaccination
mononuclear leukocytes
Assays
vaccination
genes
Patient monitoring
Clone Cells
Physiologic Monitoring

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Detection and tracking of NY-ESO-1-Specific CD8+ T cells by high-throughput T cell receptor β (TCRB) gene rearrangements sequencing in a peptide-vaccinated patient. / Miyai, Manami; Eikawa, Shingo; Hosoi, Akihiro; Iino, Tamaki; Matsushita, Hirokazu; Isobe, Midori; Uenaka, Akiko; Udono, Heiichiro; Nakajima, Jun; Nakayama, Eiichi; Kakimi, Kazuhiro.

In: PLoS One, Vol. 10, No. 8, e0136086, 20.08.2015.

Research output: Contribution to journalArticle

Miyai, M, Eikawa, S, Hosoi, A, Iino, T, Matsushita, H, Isobe, M, Uenaka, A, Udono, H, Nakajima, J, Nakayama, E & Kakimi, K 2015, 'Detection and tracking of NY-ESO-1-Specific CD8+ T cells by high-throughput T cell receptor β (TCRB) gene rearrangements sequencing in a peptide-vaccinated patient', PLoS One, vol. 10, no. 8, e0136086. https://doi.org/10.1371/journal.pone.0136086
Miyai, Manami ; Eikawa, Shingo ; Hosoi, Akihiro ; Iino, Tamaki ; Matsushita, Hirokazu ; Isobe, Midori ; Uenaka, Akiko ; Udono, Heiichiro ; Nakajima, Jun ; Nakayama, Eiichi ; Kakimi, Kazuhiro. / Detection and tracking of NY-ESO-1-Specific CD8+ T cells by high-throughput T cell receptor β (TCRB) gene rearrangements sequencing in a peptide-vaccinated patient. In: PLoS One. 2015 ; Vol. 10, No. 8.
@article{277dd33ff0bf46188c62357927916b6c,
title = "Detection and tracking of NY-ESO-1-Specific CD8+ T cells by high-throughput T cell receptor β (TCRB) gene rearrangements sequencing in a peptide-vaccinated patient",
abstract = "Comprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high responder patient (TK-f01) in an NY-ESO-1f peptide vaccine study, we performed high-throughput T cell receptor β-chain (TCRB) gene next generation sequencing (NGS) to monitor the frequency of NY-ESO-1-specific CD8+ T cells. We compared these results with those of conventional immunological assays, such as IFN-γ capture, tetramer binding and limiting dilution clonality assays. We sequenced human TCRB complementarity-determining region 3 (CDR3) rearrangements of two NY-ESO-1fspecific CD8+ T cell clones, 6-8L and 2F6, as well as PBMCs over the course of peptide vaccination. Clone 6-8L possessed the TCRB CDR3 gene TCRBV11-03∗01 and BJ02- 01∗01 with amino acid sequence CASSLRGNEQFF, whereas 2F6 possessed TCRBV05- 08∗01 and BJ02-04∗01 (CASSLVGTNIQYF). Using these two sequences as models, we evaluated the frequency of NY-ESO-1-specific CD8+ T cells in PBMCs ex vivo. The 6-8L CDR3 sequence was the second most frequent in PBMC and was present at high frequency (0.7133{\%}) even prior to vaccination, and sustained over the course of vaccination. Despite a marked expansion of NY-ESO-1-specific CD8+ T cells detected from the first through 6th vaccination by tetramer staining and IFN-γ capture assays, as evaluated by CDR3 sequencing the frequency did not increase with increasing rounds of peptide vaccination. By clonal analysis using 12 day in vitro stimulation, the frequency of B∗52:01-restricted NYESO- 1f peptide-specific CD8+ T cells in PBMCs was estimated as only 0.0023{\%}, far below the 0.7133{\%} by NGS sequencing. Thus, assays requiring in vitro stimulation might be underestimating the frequency of clones with lower proliferation potential. High-throughput TCRB sequencing using NGS can potentially better estimate the actual frequency of antigen- specific T cells and thus provide more accurate patient monitoring.",
author = "Manami Miyai and Shingo Eikawa and Akihiro Hosoi and Tamaki Iino and Hirokazu Matsushita and Midori Isobe and Akiko Uenaka and Heiichiro Udono and Jun Nakajima and Eiichi Nakayama and Kazuhiro Kakimi",
year = "2015",
month = "8",
day = "20",
doi = "10.1371/journal.pone.0136086",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Detection and tracking of NY-ESO-1-Specific CD8+ T cells by high-throughput T cell receptor β (TCRB) gene rearrangements sequencing in a peptide-vaccinated patient

AU - Miyai, Manami

AU - Eikawa, Shingo

AU - Hosoi, Akihiro

AU - Iino, Tamaki

AU - Matsushita, Hirokazu

AU - Isobe, Midori

AU - Uenaka, Akiko

AU - Udono, Heiichiro

AU - Nakajima, Jun

AU - Nakayama, Eiichi

AU - Kakimi, Kazuhiro

PY - 2015/8/20

Y1 - 2015/8/20

N2 - Comprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high responder patient (TK-f01) in an NY-ESO-1f peptide vaccine study, we performed high-throughput T cell receptor β-chain (TCRB) gene next generation sequencing (NGS) to monitor the frequency of NY-ESO-1-specific CD8+ T cells. We compared these results with those of conventional immunological assays, such as IFN-γ capture, tetramer binding and limiting dilution clonality assays. We sequenced human TCRB complementarity-determining region 3 (CDR3) rearrangements of two NY-ESO-1fspecific CD8+ T cell clones, 6-8L and 2F6, as well as PBMCs over the course of peptide vaccination. Clone 6-8L possessed the TCRB CDR3 gene TCRBV11-03∗01 and BJ02- 01∗01 with amino acid sequence CASSLRGNEQFF, whereas 2F6 possessed TCRBV05- 08∗01 and BJ02-04∗01 (CASSLVGTNIQYF). Using these two sequences as models, we evaluated the frequency of NY-ESO-1-specific CD8+ T cells in PBMCs ex vivo. The 6-8L CDR3 sequence was the second most frequent in PBMC and was present at high frequency (0.7133%) even prior to vaccination, and sustained over the course of vaccination. Despite a marked expansion of NY-ESO-1-specific CD8+ T cells detected from the first through 6th vaccination by tetramer staining and IFN-γ capture assays, as evaluated by CDR3 sequencing the frequency did not increase with increasing rounds of peptide vaccination. By clonal analysis using 12 day in vitro stimulation, the frequency of B∗52:01-restricted NYESO- 1f peptide-specific CD8+ T cells in PBMCs was estimated as only 0.0023%, far below the 0.7133% by NGS sequencing. Thus, assays requiring in vitro stimulation might be underestimating the frequency of clones with lower proliferation potential. High-throughput TCRB sequencing using NGS can potentially better estimate the actual frequency of antigen- specific T cells and thus provide more accurate patient monitoring.

AB - Comprehensive immunological evaluation is crucial for monitoring patients undergoing antigen-specific cancer immunotherapy. The identification and quantification of T cell responses is most important for the further development of such therapies. Using well-characterized clinical samples from a high responder patient (TK-f01) in an NY-ESO-1f peptide vaccine study, we performed high-throughput T cell receptor β-chain (TCRB) gene next generation sequencing (NGS) to monitor the frequency of NY-ESO-1-specific CD8+ T cells. We compared these results with those of conventional immunological assays, such as IFN-γ capture, tetramer binding and limiting dilution clonality assays. We sequenced human TCRB complementarity-determining region 3 (CDR3) rearrangements of two NY-ESO-1fspecific CD8+ T cell clones, 6-8L and 2F6, as well as PBMCs over the course of peptide vaccination. Clone 6-8L possessed the TCRB CDR3 gene TCRBV11-03∗01 and BJ02- 01∗01 with amino acid sequence CASSLRGNEQFF, whereas 2F6 possessed TCRBV05- 08∗01 and BJ02-04∗01 (CASSLVGTNIQYF). Using these two sequences as models, we evaluated the frequency of NY-ESO-1-specific CD8+ T cells in PBMCs ex vivo. The 6-8L CDR3 sequence was the second most frequent in PBMC and was present at high frequency (0.7133%) even prior to vaccination, and sustained over the course of vaccination. Despite a marked expansion of NY-ESO-1-specific CD8+ T cells detected from the first through 6th vaccination by tetramer staining and IFN-γ capture assays, as evaluated by CDR3 sequencing the frequency did not increase with increasing rounds of peptide vaccination. By clonal analysis using 12 day in vitro stimulation, the frequency of B∗52:01-restricted NYESO- 1f peptide-specific CD8+ T cells in PBMCs was estimated as only 0.0023%, far below the 0.7133% by NGS sequencing. Thus, assays requiring in vitro stimulation might be underestimating the frequency of clones with lower proliferation potential. High-throughput TCRB sequencing using NGS can potentially better estimate the actual frequency of antigen- specific T cells and thus provide more accurate patient monitoring.

UR - http://www.scopus.com/inward/record.url?scp=84942916791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942916791&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0136086

DO - 10.1371/journal.pone.0136086

M3 - Article

C2 - 26291626

AN - SCOPUS:84942916791

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0136086

ER -